Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
about
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case reportInfluence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.PharmGKB summary: voriconazole pathway, pharmacokinetics.High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.
P2860
Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Putting CYP2C19 genotyping to ...... le-treated haematology cohort.
@en
type
label
Putting CYP2C19 genotyping to ...... le-treated haematology cohort.
@en
prefLabel
Putting CYP2C19 genotyping to ...... le-treated haematology cohort.
@en
P2860
P50
P356
P1476
Putting CYP2C19 genotyping to ...... ole-treated haematology cohort
@en
P2093
P2860
P304
P356
10.1093/JAC/DKU529
P407
P577
2015-01-03T00:00:00Z